GSK, Shingles
Benzinga.com · 2d
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The results will support regulatory submissions to the FDA and EMA.
The Pharma Letter · 2d
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial showed that co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ produced a non-inferior immune response and was well tolerated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results